pmjТихоокеанский медицинский журналPacific Medical Journal1609-1175TGMU10.34215/1609-1175-2025-2-50-54pmj-2926Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL RESEARCHESФармакологические мишени стволовых клеток глиобластомыPharmacological targets of glioblastoma stem cellshttps://orcid.org/0000-0002-1312-8308ЗайцевС. В.ZaitsevS. V.

Зайцев Сергей Викторович – канд. биол. наук, зав. лабораторией молекулярной и клеточной нейробиологии департамента фармации и фармакологии Школы медицины и наук о жизни

690922, г. Владивосток, о. Русский, п. Аякс, 10

Sergey V. Zaitsev, Cand. Sci. (Biol.), Head of the Laboratory, Department of Pharmacy and Pharmacology, School of Medicine and Life Sciences

10 Ajax Bay, Russky Island, Vladivostok, 690922

zaytcev.svi@dvfu.ruПугачеваЕ. С.PugachevaE. S.

690922, г. Владивосток, о. Русский, п. Аякс, 10

10 Ajax Bay, Russky Island, Vladivostok, 690922

КосьяноваА. А.Kos'yanovaA. A.

690922, г. Владивосток, о. Русский, п. Аякс, 10

10 Ajax Bay, Russky Island, Vladivostok, 690922

ПакО. И.PakO. I.

690922, г. Владивосток, о. Русский, п. Аякс, 10

10 Ajax Bay, Russky Island, Vladivostok, 690922

БрюховецкийИ. С.BryukhovetskiyI. S.

690922, г. Владивосток, о. Русский, п. Аякс, 10

10 Ajax Bay, Russky Island, Vladivostok, 690922

Дальневосточный федеральный университетРоссияEastern Federal UniversityRussian FederationДальневосточный федеральный университет; Национальный научный центр морской биологии им. А.В. Жирмунского ДВО РАНРоссияEastern Federal University; A.V. Zhirmunsky National Marine Biology Research CenterRussian Federation202511082025025054Copyright © Зайцев С.В., Пугачева Е.С., Косьянова А.А., Пак О.И., Брюховецкий И.С., 20252025Зайцев С.В., Пугачева Е.С., Косьянова А.А., Пак О.И., Брюховецкий И.С.Zaitsev S.V., Pugacheva E.S., Kos'yanova A.A., Pak O.I., Bryukhovetskiy I.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tmj-vgmu.ru/jour/article/view/2926

Цель: поиск фармакологических мишеней для повышения эффективности химиолучевой терапии. Материалы и методы: использован высокочувствительный транскриптомный анализ на микрочипах высокой плотности, рутинные клеточные технологии и современный биоинформационный анализ. Результаты: идентифицировано 677 генов CD133+ ОСК, усиливших экспрессию в 2 и более раз по сравнению с дифференцированными ОК (ДОК): выявлено 13 транскпиптов, критически усиливших уровень синтеза в ОСК (> 4 раз): akt1, hdac1, cnnb1, ahnak2, daam, pik3cg, mctp1, Il31ra, ca9, csnk2b, col6a1, col6a3 и lambd1. Заключение: фармакологическими мишенями в ОСК являются белки АКТ1, HDAC1, CTNNB1 – продукты экспрессии генов akt1, hdac1, ctnnb1, к целям второго порядка следует отнести белковые продукты генов ahnak2, daam, pik3cg, mctp1, Il31ra, ca9, csnk2b, col6a1, col6a3 и lambd1

Objective. To identify pharmacological targets to enhance the effectiveness of chemoradiotherapy. Materials and methods. A highly sensitive transcriptomic analysis using high-density microarrays, routine cell technologies, and advanced bioinformatic analysis were employed.  Results. A total of 677 genes were identified in CD133+ glioblastoma stem cells (GSCs) with expression levels increased by two-fold or more compared to differentiated glioblastoma cells (DGCs). Among them, 13 transcripts demonstrated a critically elevated expression in GSCs (more than 4-fold), including: akt1, hdac1, cnnb1, ahnak2, daam, pik3cg, mctp1, Il31ra, ca9, csnk2b, col6a1, col6a3 and lambd1. Conclusion. The primary pharmacological targets in glioblastoma stem cells (GSCs) are the proteins AKT1, HDAC1, and CTNNB1 – the products of the akt1, hdac1, and ctnnb1 genes. Secondary targets include the protein products of the ahnak2, daam, pik3cg, mctp1, il31ra, ca9, csnk2b, col6a1, col6a3, and lambd1 genes

глиобластомаопухолевые стволовые клеткифармакологические мишениglioblastomacancer stem cellspharmacological targetsАвторы заявляют о финансировании проведенного исследования из собственных средствReferencesSchaff LR, Mellinghoff IK. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023 Feb 21;329(7):574–587. doi: 10.1001/jama.2023.0023Schaff LR, Mellinghoff IK. Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA. 2023 Feb 21;329(7):574–587. doi: 10.1001/jama.2023.0023Sloan AR, Silver DJ, Kint S, Gallo M, Lathia JD. Cancer stem cell hypothesis 2.0 in glioblastoma: Where are we now and where are we going? Neuro Oncol. 2024 May 3;26(5):785–795. doi: 10.1093/neuonc/noae011Sloan AR, Silver DJ, Kint S, Gallo M, Lathia JD. Cancer stem cell hypothesis 2.0 in glioblastoma: Where are we now and where are we going? Neuro Oncol. 2024 May 3;26(5):785–795. doi: 10.1093/neuonc/noae011Yabo YA, Niclou SP, Golebiewska A. Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma. Neuro Oncol. 2022 May 4;24(5):669–682. doi: 10.1093/neuonc/noab269Yabo YA, Niclou SP, Golebiewska A. Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma. Neuro Oncol. 2022 May 4;24(5):669–682. doi: 10.1093/neuonc/noab269Kim KH, Migliozzi S, Koo H, Hong JH, Park SM, Kim S, Kwon HJ, Ha S, Garofano L, Oh YT, D'Angelo F, Kim CI, Kim S, Lee JY, Kim J, Hong J, Jang EH, Mathon B, Di Stefano AL, Bielle F, Laurenge A, Nesvizhskii AI, Hur EM, Yin J, Shi B, Kim Y, Moon KS, Kwon JT, Lee SH, Lee SH, Gwak HS, Lasorella A, Yoo H, Sanson M, Sa JK, Park CK, Nam DH, Iavarone A, Park JB. Integrated proteogenomic characterization of glioblastoma evolution. Cancer Cell. 2024 Mar 11;42(3):358–377.e8. doi: 10.1016/j.ccell.2023.12.015Kim KH, Migliozzi S, Koo H, Hong JH, Park SM, Kim S, Kwon HJ, Ha S, Garofano L, Oh YT, D'Angelo F, Kim CI, Kim S, Lee JY, Kim J, Hong J, Jang EH, Mathon B, Di Stefano AL, Bielle F, Laurenge A, Nesvizhskii AI, Hur EM, Yin J, Shi B, Kim Y, Moon KS, Kwon JT, Lee SH, Lee SH, Gwak HS, Lasorella A, Yoo H, Sanson M, Sa JK, Park CK, Nam DH, Iavarone A, Park JB. Integrated proteogenomic characterization of glioblastoma evolution. Cancer Cell. 2024 Mar 11;42(3):358–377.e8. doi: 10.1016/j.ccell.2023.12.015Bryukhovetskiy I. Cell-based immunotherapy of glioblastoma multiforme. Oncol Lett. 2022 Apr;23(4):133. doi: 10.3892/ol.2022.13253Bryukhovetskiy I. Cell-based immunotherapy of glioblastoma multiforme. Oncol Lett. 2022 Apr;23(4):133. doi: 10.3892/ol.2022.13253Srivastava R, Dodda M, Zou H, Li X, Hu B. Tumor Niches: Perspectives for Targeted Therapies in Glioblastoma. Antioxid Redox Signal. 2023 Nov;39(13–15):904–922. doi: 10.1089/ars.2022.0187Srivastava R, Dodda M, Zou H, Li X, Hu B. Tumor Niches: Perspectives for Targeted Therapies in Glioblastoma. Antioxid Redox Signal. 2023 Nov;39(13–15):904–922. doi: 10.1089/ars.2022.0187Barzegar Behrooz A, Talaie Z, Jusheghani F, Łos MJ, Klonisch T, Ghavami S. Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma. Int J Mol Sci. 2022 Jan 25;23(3):1353. doi: 10.3390/ijms23031353Barzegar Behrooz A, Talaie Z, Jusheghani F, Łos MJ, Klonisch T, Ghavami S. Wnt and PI3K/Akt/mTOR Survival Pathways as Therapeutic Targets in Glioblastoma. Int J Mol Sci. 2022 Jan 25;23(3):1353. doi: 10.3390/ijms23031353Manoranjan B, Chokshi C, Venugopal C, Subapanditha M, Savage N, Tatari N, Provias JP, Murty NK, Moffat J, Doble BW, Singh SK. A CD133-AKT-Wnt signaling axis drives glioblastoma brain tumor-initiating cells. Oncogene. 2020 Feb;39(7):1590– 1599. doi: 10.1038/s41388-019-1086-xManoranjan B, Chokshi C, Venugopal C, Subapanditha M, Savage N, Tatari N, Provias JP, Murty NK, Moffat J, Doble BW, Singh SK. A CD133-AKT-Wnt signaling axis drives glioblastoma brain tumor-initiating cells. Oncogene. 2020 Feb;39(7):1590– 1599. doi: 10.1038/s41388-019-1086-xJung KH, Lee JH, Kim M, Lee EJ, Cho YS, Lee KH. Celecoxib- Induced Modulation of Colon Cancer CD133 Expression Occurs through AKT Inhibition and Is Monitored by 89Zr Immuno-PET. Mol Imaging. 2022 Jan 7;2022:4906934. doi: 10.1155/2022/4906934Jung KH, Lee JH, Kim M, Lee EJ, Cho YS, Lee KH. Celecoxib- Induced Modulation of Colon Cancer CD133 Expression Occurs through AKT Inhibition and Is Monitored by 89Zr Immuno-PET. Mol Imaging. 2022 Jan 7;2022:4906934. doi: 10.1155/2022/4906934Liu DX, Hao SL, Yang WX. Crosstalk Between beta-CATENINMediated Cell Adhesion and the WNT Signaling Pathway. DNA Cell Biol. 2023 Jan;42(1):1–13. doi: 10.1089/dna.2022.0424Liu DX, Hao SL, Yang WX. Crosstalk Between beta-CATENINMediated Cell Adhesion and the WNT Signaling Pathway. DNA Cell Biol. 2023 Jan;42(1):1–13. doi: 10.1089/dna.2022.0424Gopinathan A, Sankhe R, Rathi E, Kodi T, Upadhya R, Pai KSR, Kishore A. An in silico drug repurposing approach to identify HDAC1 inhibitors against glioblastoma. J Biomol Struct Dyn. 2024 Apr 30:1–14. doi: 10.1080/07391102.2024.2335293Gopinathan A, Sankhe R, Rathi E, Kodi T, Upadhya R, Pai KSR, Kishore A. An in silico drug repurposing approach to identify HDAC1 inhibitors against glioblastoma. J Biomol Struct Dyn. 2024 Apr 30:1–14. doi: 10.1080/07391102.2024.2335293Zhang BT, Leung PC, Wong CK, Wang DJ. The Immunomodulatory Effects of Vitamin D on COVID-19 Induced Glioblastoma Recurrence via the PI3K-AKT Signaling Pathway. Int J Mol Sci. 2024 Dec 2;25(23):12952. doi: 10.3390ijms252312952Zhang BT, Leung PC, Wong CK, Wang DJ. The Immunomodulatory Effects of Vitamin D on COVID-19 Induced Glioblastoma Recurrence via the PI3K-AKT Signaling Pathway. Int J Mol Sci. 2024 Dec 2;25(23):12952. doi: 10.3390ijms252312952Hashemi M, Etemad S, Rezaei S, Ziaolhagh S, Rajabi R, Rahmanian P, Abdi S, Koohpar ZK, Rafiei R, Raei B, Ahmadi F, Salimimoghadam S, Aref AR, Zandieh MA, Entezari M, Taheriazam A, Hushmandi K. Progress in targeting PTENPI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions. Biomed Pharmacother. 2023 Feb;158:114204. doi: 10.1016/j.biopha.2022.114204Hashemi M, Etemad S, Rezaei S, Ziaolhagh S, Rajabi R, Rahmanian P, Abdi S, Koohpar ZK, Rafiei R, Raei B, Ahmadi F, Salimimoghadam S, Aref AR, Zandieh MA, Entezari M, Taheriazam A, Hushmandi K. Progress in targeting PTENPI3K/Akt axis in glioblastoma therapy: Revisiting molecular interactions. Biomed Pharmacother. 2023 Feb;158:114204. doi: 10.1016/j.biopha.2022.114204Zhang C, Wang M, Ji F, Peng Y, Wang B, Zhao J, Wu J, Zhao H. A Novel Glucose Metabolism-Related Gene Signature for Overall Survival Prediction in Patients with Glioblastoma. Biomed Res Int. 2021 Jan 22;2021:8872977. doi: 10.1155/2021/8872977Zhang C, Wang M, Ji F, Peng Y, Wang B, Zhao J, Wu J, Zhao H. A Novel Glucose Metabolism-Related Gene Signature for Overall Survival Prediction in Patients with Glioblastoma. Biomed Res Int. 2021 Jan 22;2021:8872977. doi: 10.1155/2021/8872977Latour M, Her NG, Kesari S, Nurmemmedov E. WNT Signaling as a Therapeutic Target for Glioblastoma. Int J Mol Sci. 2021 Aug 5;22(16):8428. doi: 10.3390/ijms22168428Latour M, Her NG, Kesari S, Nurmemmedov E. WNT Signaling as a Therapeutic Target for Glioblastoma. Int J Mol Sci. 2021 Aug 5;22(16):8428. doi: 10.3390/ijms22168428

The authors declare that there are no conflicts of interest present.